National Institutes of Health

Advancing Real-World Effectiveness Evidence for Rapid-Acting Psychotropic Interventional Drugs (RAPIDs) (UM1 Clinical Trial Required)

What it funds

This notice of funding opportunity (NOFO) encourages applications to establish a Rapid-Acting Psychotropic Interventional Drugs - Clinical Trials Network (RAPIDs-CTN). The overarching purpose is to generate actionable, real-world evidence to guide the safe and effective implementation of RAPIDs in routine clinical practice, answering urgent questions about how these treatments can be delivered sustainably outside tightly controlled experimental settings. This NOFO utilizes a milestone-driven UM1 Cooperative Agreement mechanism structured into two operational stages: Stage 1 (Years 1–2) for network establishment and pilot studies, and Stage 2 (Years 3–5) focuses for full-scale execution of proposed pragmatic trials. This program is intended only for large-scale, coordinated network projects that could not be achieved using other, more standard grant mechanisms.

Who can apply

Other Eligible ApplicantsIndian/Native American Tribal Governments (Other than Federally Recognized);Eligible Agencies of the Federal Government;U.S. Territory or Possession;Faith-based or Community-based Organizations;Regional Organizations;

How to apply

Read the full notice and application package on the official listing, RFA-MH-27-150 on Grants.gov. Questions go to [email protected]. Make sure your SAM.gov registration and Grants.gov or agency portal accounts are active well before the deadline, since registration can take several weeks.

Last updated by the agency Nov 11, 2026. Tracked by Federal Runway since Nov 17, 2026. Confirm details on the official notice.

Related opportunities